Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | June 05, 2026 | June 09, 2026 |
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Director | May 15, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 30,000 · Balance 30,000 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2036-06-05 | Direct | 60,000 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 60,000 · Balance 60,000 F2: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
F2: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
TriSalus Life Sciences, Inc.
Report date May 15, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 147,555 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Purchase · Acquired 60,000 · Balance 147,555 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
| Common StockSEC Table I · non-derivative | IndirectBy Leonard Capital LLC | 1,444,447 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,444,447 F2: The Reporting Person shares voting and investment discretion with his spouse with respect to the shares held directly by Leonard Capital LLC. |
| Common StockSEC Table I · non-derivative | IndirectBy HW Investment Partners, LLC | 1,370,028 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,370,028 F3: The Reporting Person is a managing member of HW Investment Partners, LLC ("HW Investment") and shares voting and investment discretion with respect to the shares held directly by HW Investment. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: The Reporting Person shares voting and investment discretion with his spouse with respect to the shares held directly by Leonard Capital LLC.
F3: The Reporting Person is a managing member of HW Investment Partners, LLC ("HW Investment") and shares voting and investment discretion with respect to the shares held directly by HW Investment. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 22:40 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001610717-26-000201 · form4.xml · derivative · entry 2 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-06-05 F2 · derivative.exercise_date: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 22:40 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000201 · form4.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:42 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 60,000 | $2.53 | $151,800.00 |
DisclosureSEC source: 0001628280-26-035996 · wk-form4_1779136958.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,555 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:39 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector Stock Option (right to buy) · Derivative | 75,204 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001628280-26-035667 · wk-form4_1778877563.xml · derivative · entry 5 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,149 Underlying: Common Stock · 75,204 shares Expires 2036-05-13 F5 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:39 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 34,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-035667 · wk-form4_1778877563.xml · nonDerivative · entry 2 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,555 F2 · shares: Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:39 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 37,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-035667 · wk-form4_1778877563.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,329 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 22:49 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001610717-25-000227 · form4.xml · derivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 11, 2025, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 12, 2025 Filed Jun 27, 2025 20:12 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001826667-25-000079 · wk-form4_1751055139.xml · derivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,945 Underlying: Common Stock · 15,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:12 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 99,988 | $0.74 | $73,881.13 |
DisclosureSEC source: 0001610717-25-000145 · form4.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Leonard Capital, LLC Disclosed balance after: 0 F1 · kind: The reported sale transactions were effected for tax planning purposes. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7362 to $0.7448, exclusive of any fees, commissions or other expenses. The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The Reporting Person and his spouse are the members of Leonard Capital, LLC and therefore the Reporting Person may be deemed to have voting and dispositive power of shares held by Leonard Capital, LLC. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 22:59 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | OtherSeries A Convertible Preferred Stock · Derivative | 44,750 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001415889-25-003621 · form4-02112025_100210.xml · derivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Leonard Capital LLC Disclosed balance after: 94,750 Underlying: Common Stock · 44,750 shares Expires not disclosed F1 · derivative.exercise_price: The conversion price (the "Conversion Price") reflects the reset effective as of February 10, 2025, which reset occurred in accordance with the terms of the Issuer's Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer filed with the Delaware Secretary of State on August 10, 2023. F2 · kind: Effective February 10, 2025, the Conversion Price of the 50,000 shares of Series A Convertible Preferred Stock (the "Preferred Stock") held by the Reporting Person was reset in accordance with the terms of the Preferred Stock, resulting in an increase in the number of shares of Common Stock issuable upon conversion of the Preferred Stock. F2 · shares: Effective February 10, 2025, the Conversion Price of the 50,000 shares of Series A Convertible Preferred Stock (the "Preferred Stock") held by the Reporting Person was reset in accordance with the terms of the Preferred Stock, resulting in an increase in the number of shares of Common Stock issuable upon conversion of the Preferred Stock. F3 · derivative.exercise_date: After giving effect to the Conversion Price reset, the Preferred Stock is convertible, in whole or in part, into 94,750 shares of Common Stock of the Issuer (based on a Conversion Price of $5.277 per share, which is subject to adjustment upon the occurrence of certain events) at any time, at the Reporting Person's election. F4 · derivative.expiration_date: All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027. F5 · derivative.underlying_shares: Represents the incremental number of shares of Common Stock that are issuable upon conversion of the Preferred Stock as a result of the Conversion Price reset. F3 · balance_after: After giving effect to the Conversion Price reset, the Preferred Stock is convertible, in whole or in part, into 94,750 shares of Common Stock of the Issuer (based on a Conversion Price of $5.277 per share, which is subject to adjustment upon the occurrence of certain events) at any time, at the Reporting Person's election. F6 · ownership.nature: The Reporting Person shares voting and investment discretion with his spouse with respect to the shares held directly by Leonard Capital LLC. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 23:07 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 25,188 | $3.97 | $99,996.36 |
DisclosureSEC source: 0001415889-24-029907 · form4-12192024_111222.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,915 F1 · shares: The shares were issued in connection with the closing of the transaction contemplated by the Securities Purchase Agreement, entered into December 12, 2024, by and between the Issuer and Reporting Person. Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 22:53 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 5,000 | $4.55 | $22,750.00 |
DisclosureSEC source: 0001415889-24-027656 · form4-11252024_101159.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,727 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.45 to $4.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 21, 2024 Filed Nov 23, 2024 00:11 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 8,687 | $4.44 | $38,570.28 |
DisclosureSEC source: 0001415889-24-027587 · form4-11232024_121118.xml · nonDerivative · entry 2 Wahlstrom Mats · CIK 0001459154 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,727 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.19 to $4.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 20, 2024 Filed Nov 23, 2024 00:11 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 2,040 | $4.16 | $8,486.40 |
DisclosureSEC source: 0001415889-24-027587 · form4-11232024_121118.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,040 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.99 to $4.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| August 13, 2024 Filed Aug 22, 2024 00:48 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector stock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001415889-24-021962 · form4-08222024_120827.xml · derivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 22:50 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001610717-24-000290 · form4.xml · derivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2034-06-03 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 3, 2024, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| February 09, 2024 Filed Feb 16, 2024 00:56 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GiftCommon Stock | 99,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000060 · form4.xml · nonDerivative · entry 2 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Leonard Capital, LLC Disclosed balance after: 99,988 F1 · kind: Reflects the transfer, for no consideration, of 99,988 shares directly owned by the Reporting Person to Leonard Capital, LLC. F2 · ownership.nature: The Reporting Person and his spouse are the members of Leonard Capital, LLC and therefore the Reporting Person may be deemed to have voting and dispositive power of shares held by Leonard Capital, LLC. Read SEC document |
| February 09, 2024 Filed Feb 16, 2024 00:56 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GiftCommon Stock | 99,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000060 · form4.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects the transfer, for no consideration, of 99,988 shares directly owned by the Reporting Person to Leonard Capital, LLC. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:03 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 44,991 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001610717-24-000044 · form4.xml · derivative · entry 4 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,991 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:03 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,997 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001610717-24-000044 · form4.xml · derivative · entry 3 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,997 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:03 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 44,991 | $1.67 | $75,000.00 |
DisclosureSEC source: 0001610717-24-000044 · form4.xml · nonDerivative · entry 2 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This represents a cash exercise-and-hold transaction where cash was paid by the Reporting Person for the exercise price. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:03 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 14,997 | $1.67 | $25,000.00 |
DisclosureSEC source: 0001610717-24-000044 · form4.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This represents a cash exercise-and-hold transaction where cash was paid by the Reporting Person for the exercise price. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 22:19 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-23-045700 · doc4.xml · derivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-08-09 F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 21:09 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 38,250 | $0.00 Strike: $5.38 | $0.00 |
DisclosureSEC source: 0001610717-23-000122 · form4.xml · derivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,250 Underlying: Common Stock · 38,250 shares Expires 2033-06-07 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from June 7, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 01:22 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,994 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001567619-22-005922 · doc1.xml · derivative · entry 3 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,994 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The underlying shares subject to the option are fully vested and exercisable. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 01:22 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 29,994 | $2.08 | $62,501.50 |
DisclosureSEC source: 0001567619-22-005922 · doc1.xml · nonDerivative · entry 2 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 01:22 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 10,006 | $11.64 | $116,432.82 |
DisclosureSEC source: 0001567619-22-005922 · doc1.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,006 Read SEC document |
| January 07, 2022 Filed Jan 10, 2022 21:30 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $15.94 | $0.00 |
DisclosureSEC source: 0001567619-22-000920 · doc1.xml · derivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-01-07 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 07, 2022 Filed Feb 11, 2022 21:11 UTC Amendment | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $14.67 | $0.00 |
DisclosureSEC source: 0001567619-22-003502 · doc1.xml · derivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-01-07 F1 · derivative.exercise_price: The Form 4/A is being filed solely to correct a typographical error in the exercise price. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported. F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:31 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001567619-21-000990 · doc1.xml · derivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:33 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 200,000 | $17.15 | $3,430,020.00 |
DisclosureSEC source: 0001567619-20-012456 · doc1.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: The transaction was executed in multiple trades in prices ranging from $17.00 to $17.3750, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are held by Leonard Capital, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by Leonard Capital, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:31 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 4,222 | $20.89 | $88,214.89 |
DisclosureSEC source: 0001567619-20-005741 · doc1.xml · nonDerivative · entry 2 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 200,000 F3 · price: The transaction was executed in multiple trades in prices ranging from $20.50 to $21.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are held by Leonard Capital, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by Leonard Capital, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:31 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 113,844 | $20.09 | $2,287,194.27 |
DisclosureSEC source: 0001567619-20-005741 · doc1.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 204,222 F1 · price: The transaction was executed in multiple trades in prices ranging from $19.50 to $20.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are held by Leonard Capital, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by Leonard Capital, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:54 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $17.73 | $0.00 |
DisclosureSEC source: 0001567619-20-001046 · doc1.xml · derivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-10 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 21:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | OtherCommon Stock, $0.0001 par value | 98,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012731 · doc1.xml · nonDerivative · entry 2 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 318,066 F1 · kind: KMG Capital Partners, LLC distributed an aggregate of 178,528 shares of common stock of the issuer to its limited and general partners for no consideration, effective May 31, 2019. Reflects pro rata allocation of such shares distributed to Leonard Capital, LLC. F3 · ownership.nature: The shares are held by Leonard Capital, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by Leonard Capital, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 21:39 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | OtherCommon Stock, $0.0001 par value | 178,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012731 · doc1.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: KMG Capital Partners, LLC distributed an aggregate of 178,528 shares of common stock of the issuer to its limited and general partners for no consideration, effective May 31, 2019. Reflects pro rata allocation of such shares distributed to Leonard Capital, LLC. F2 · ownership.nature: The shares are held by KMG Capital Partners, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by KMG Capital Partners, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| January 11, 2019 Filed Jan 30, 2019 21:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.37 | $0.00 |
DisclosureSEC source: 0000899243-19-002188 · doc4.xml · derivative · entry 3 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-11 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002881 · doc4.xml · derivative · entry 3 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-01 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $23.80 | $0.00 |
DisclosureSEC source: 0000899243-17-013888 · doc4.xml · derivative · entry 5 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-17 F5 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from May 17, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 09, 2017 Filed May 19, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | OtherCommon Stock, $0.0001 par value | 109,957 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-013888 · doc4.xml · nonDerivative · entry 4 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 219,914 F4 · kind: KMG Capital Partners, LLC distributed an aggregate of 200,000 shares of common stock of the issuer to its limited and general partners for no consideration on April 27, 2017. Reflects pro rata allocation of such shares distributed to Leonard Capital, LLC. F3 · ownership.nature: The shares are held by Leonard Capital, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by Leonard Capital, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| May 09, 2017 Filed May 19, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | OtherCommon Stock, $0.0001 par value | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-013888 · doc4.xml · nonDerivative · entry 3 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 178,528 F4 · kind: KMG Capital Partners, LLC distributed an aggregate of 200,000 shares of common stock of the issuer to its limited and general partners for no consideration on April 27, 2017. Reflects pro rata allocation of such shares distributed to Leonard Capital, LLC. F2 · ownership.nature: The shares are held by KMG Capital Partners, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by KMG Capital Partners, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| February 22, 2017 Filed May 19, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | OtherCommon Stock, $0.0001 par value | 109,957 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-013888 · doc4.xml · nonDerivative · entry 2 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 109,957 F1 · kind: KMG Capital Partners, LLC distributed an aggregate of 200,000 shares of common stock of the issuer to its limited and general partners for no consideration on February 22, 2017. Reflects pro rata allocation of such shares distributed to Leonard Capital, LLC. F3 · ownership.nature: The shares are held by Leonard Capital, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by Leonard Capital, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| February 22, 2017 Filed May 19, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | OtherCommon Stock, $0.0001 par value | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-013888 · doc4.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 378,528 F1 · kind: KMG Capital Partners, LLC distributed an aggregate of 200,000 shares of common stock of the issuer to its limited and general partners for no consideration on February 22, 2017. Reflects pro rata allocation of such shares distributed to Leonard Capital, LLC. F2 · ownership.nature: The shares are held by KMG Capital Partners, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by KMG Capital Partners, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| December 08, 2016 Filed Dec 9, 2016 21:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 46,190 | $27.52 | $1,271,347.42 |
DisclosureSEC source: 0000899243-16-035219 · doc4.xml · nonDerivative · entry 2 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F3 · price: The transaction was executed in multiple trades in prices ranging from $27.50 to $27.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are held by Leonard Capital, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by Leonard Capital, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 21:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 7,393 | $27.50 | $203,329.68 |
DisclosureSEC source: 0000899243-16-035219 · doc4.xml · nonDerivative · entry 1 Wahlstrom Mats · CIK 0001459154 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,190 F1 · price: The transaction was executed in multiple trades in prices ranging from $27.50 to $27.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are held by Leonard Capital, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by Leonard Capital, LLC except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.